TCL Archive NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA. July 13, 2007
TCL Archive Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says September 6, 2002